ClinicalTrials.gg
CompletedNCT04925713Updated Aug 2, 2024Results posted

IFx-Hu2.0 for the Treatment of Patients With Skin Cancer

A Phase 1 interventional study of IFx-Hu2.0 in Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma, sponsored by TuHURA Biosciences, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by TuHURA Biosciences, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Enrollment
128th of 139
5 · median 40
Started
2021
with 12 others
Phase 1
36 of 171
4 open now
Registered
128th of 171
by date

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 128th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2021, is one of 36 in phase 1, and was the 128th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed adverse events..

Read the detailed description

This is a multi-site, open-label, interventional, prospective, phase 1 trial to assess safety and tolerability of IFx-Hu2.0 in patients with basal cell carcinoma, squamous cell carcinoma, or cutaneous melanoma.

A total of approximately one hundred (100) male and/or female adult patients (greater than or equal to 18 years old), of any ethnicity and race, with at least one cutaneous melanoma, squamous cell carcinoma, or basal cell carcinoma lesion accessible for direct injection, who meet all inclusion and no exclusion criteria, will be eligible for enrollment and treatment with IFx-Hu2.0.

Enrollees will receive IFx-Hu2.0 as a single intralesional injection at a single time point. The target dose will be 100 μg of plasmid DNA per lesion injected at a final dose volume of 200 μL per lesion. The injected lesion will be completely excised at the follow-up visit four weeks later and will be biopsied for confirmation of diagnosis and for the establishment of a pathological response baseline peripheral blood will be collected from these patients prior to treatment administration and at the follow-up visit four weeks later. These samples will be used to perform complete blood counts (CBC) and clinical chemistry tests. A urine sample will be obtained for urinalysis for protein and blood at the same frequency. Blood samples will be drawn for immune response evaluation as well.

03

Conditions studied

  • Cutaneous Squamous Cell Carcinoma
  • Basal Cell Carcinoma

Keywords

  • cSCC
  • BCC
  • pAc/emm55
  • IFx-Hu2.0
  • Gene Therapy
  • Immunotherapy
  • Oncology
  • Immunology
  • plasmid DNA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Ability to receive intralesional injections
  4. Male or female, aged ≥ 18 years
  5. confirmed cutaneous squamous cell carcinoma, or basal cell carcinoma with accessible lesions (based on or new tissue biopsy for histological confirmation)
  6. of at least 24 weeks at the time of screening
  7. (ECOG) performance status of 0 to 1
  8. Must have greater than 3 mm
  9. At least one injectable lesion
  10. Adequate organ function as defined below (Note: these screening laboratory tests must be obtained within two weeks prior to the baseline visit, Day 0):

    10.1. (Hb) >10 g/dL 10.2. (ANC) >1,500 cells/mcL 10.3. Count (PLT) >75,000/mcL 10.4. (PT) or International Normalized Ratio (INR) ≤1.5 times the institutional unless patient is receiving anticoagulant therapy as long as PT or INR is within therapeutic range of the intended use of anticoagulants.

    10.5. Activated Partial Thromboplastin Time (aPTT) ≤1.5 times the institutional ULN unless patient is receiving anticoagulant therapy as long as aPTT is within therapeutic range of the intended use of anticoagulants.

    10.6. Serum Creatinine (SCr) ≤1.5 times the institutional ULN 10.7. Total ≤1.5 times the institutional ULN 10.8. (AST) ≤3 times the institutional ULN 10.9. Alanine Aminotransferase (ALT) ≤3 times the institutional ULN 10.10. Lactate Dehydrogenase (LDH) ≤2 times the institutional ULN 10.11. Alkaline Phosphatase (ALP) ≤2.5 times the institutional ULN 10.12. Gamma GT (GGT) ≤2.5 times the institutional ULN

  11. Lymphocyte count ≥500,000 cells/mL
  12. For females of : must have a negative urine or serum pregnancy test result within 24 hours prior to receiving IFx-Hu2.0; must use highly effective (e.g.,licensed hormonal or barrier methods) for at least one month prior to screening and agreement to use such a method during study participation and for an additional 26 weeks after the end of study treatment
  13. For males of reproductive potential: use of barrier method or other methods to ensure effective contraception with partner

Exclusion criteria

Exclusion Criteria:

  1. Concurrent participation in any other clinical trial
  2. Inability to consent for self
  3. Lesions on scalp with bone erosions must not be selected as injection sites for IFx-Hu2.0
  4. of fewer than 24 weeks at the time of screening
  5. Prior systemic anti-cancer treatment within three weeks from start of treatment (Day 0)
  6. Treatment with any product within the three weeks preceding injection
  7. Concurrent chemotherapy or biological therapy. Concurrent radiotherapy is allowed as long as it is not the same site as the injected lesion.
  8. Current treatment with systemic (greater than 10 mg of daily prednisone) doses or other immunosuppressants such as those needed for solid organ transplants. Medications needed to treat conditions such as reactive airway disease are not excluded.
  9. Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 26 weeks after the last dose of trial treatment
  10. Immunizations for encapsulated bacteria were not given for patients who have undergone a splenectomy
  11. Serious underlying medical or psychiatric conditions, active infections requiring the use of antimicrobial drugs, or active bleeding that would make the subject unsuitable or unable to participate in the study
  12. Active (HIV)/Acquired Immunodeficiency Syndrome (AIDS) or /C. Patients with treated HIV/AIDS or Hepatitis B/C with no evidence of active infection may be enrolled
  13. History of organ allograft transplantation
  14. Presence of any uncontrolled and significant medical or psychiatric condition which would interfere with trial safety assessments
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion

    One hundred (100) patients will receive 0.1 mg of IFx-Hu2.0 injected intratumorally in a single lesion at a single time point and be followed-up 28 days thereafter.

    Biological: IFx-Hu2.0

Interventions

  • BiologicalIFx-Hu2.0

    The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer. Therapeutic Classification: * Immunomodulatory Agent Route of Administration: * Intralesional (i.e. injection of cutaneous, subcutaneous or lymph nodal lesions) Mechanism of Action: * Injection of IFx-Hu2.0 into the lesion facilitates the expression of the immunogenic Emm55 protein by the tumor cells. Physiological Effect: * Expression of the emm55 gene by the tumor cells triggers immune recognition of tumor-specific and -associated antigens which leads to innate and adaptive immune responses.

    Also known as: pAc/emm55

06

What researchers measure

Primary outcomes

  1. Rate of Adverse Events

    Rate of Adverse Events reported per Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: 28 days post injection

  2. Number of Patients Who Completed the Trial [Time Frame: 28 Days Post Injection]

    Number of Patients who completed the trial per protocol without major deviations.

    Time frame: 28 days post injection

07

Results

Posted Aug 2, 2024

Participant flow

Participant flow — Overall Study
MilestoneIFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion
Started5
Completed5
Not completed0

Outcome measures

PrimaryRate of Adverse Events

Rate of Adverse Events reported per Common Terminology Criteria for Adverse Events (CTCAE) v5.0

Time frame:
28 days post injection
Reported as:
Count of participants · Participants
Rate of Adverse Events
ParticipantsIFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion
Serious Adverse Events (SAEs)0
Dose Limiting Toxicity (DLT)0
Participants Analyzed5
PrimaryNumber of Patients Who Completed the Trial [Time Frame: 28 Days Post Injection]

Number of Patients who completed the trial per protocol without major deviations.

Time frame:
28 days post injection
Reported as:
Count of participants · Participants
Number of Patients Who Completed the Trial [Time Frame: 28 Days Post Injection]
ParticipantsIFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion
Number of Patients who completed the trial5
Number of Patients who did not completed the trial0

Adverse events

Collected over Day 0 to 28 days ± 7 business days from the last dose administered.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion0/5 (0%)0/5 (0%)0/5 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion
<=18 years0
Between 18 and 65 years3
>=65 years2
Sex: Female, Male
Sex: Female, Male(Participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion
Female3
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion
Hispanic or Latino0
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White5
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion
United States5
Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma(Participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion
Count of participants2
Basal Cell Carcinoma
Basal Cell Carcinoma(Participants)IFx-Hu2.0 (Plasmid DNA) 0.1 mg/Lesion
Count of participants3
08

Study locations

1 site
  • Moore Clinical Research
    Brandon, Florida 33716, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Oct 2021, 3 months.

Results were first posted in Aug 2024, 2 years 9 months after primary completion.

Of 28 phase 1 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 51. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2021
First posted
Jun 14, 2021
StartActual
Jun 10, 2021
Primary completionActual
Oct 7, 2021
CompletionActual
Mar 10, 2022
Results first posted
Aug 2, 2024
Last update
Aug 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04925713
Lead sponsor
TuHURA Biosciences, Inc.
Responsible party
Sponsor
First posted
Jun 14, 2021
Start date
Jun 10, 2021
Primary completion
Oct 7, 2021
Completion
Mar 10, 2022
Results posted
Aug 2, 2024
Last update
Aug 2, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: pDNA-encoding Emm55 Autologous Cancer Cell Vaccine IFx-Hu2.0

Start the discussion